Skip to content

Astellas Pharma vs Urovant Sciences

Astellas Pharma logo

Astellas Pharma

Astellas is committed to turning innovative science into VALUE for patients

12296 employees · est. 2005

VS
Urovant Sciences logo

Urovant Sciences

is part of Sumitomo Pharma America as of July 2023

97 employees · est. 2017 · Irvine, United States

Astellas Pharma is the older company (2005 vs 2017); Astellas Pharma is the larger of the two.

Side-by-Side Comparison

Astellas Pharma Urovant Sciences
Founded
2005 older 2017
Headquarters
Not tracked yet Irvine, United States
Employees
12296 larger 97
Funding Stage
IPO IPO
Total Funding
Not tracked yet $240.00M
Funding Rounds
2 2
Services
Research and Development, Drug Discovery, Clinical Trials, Manufacturing and Supply, Digital Transformation, External Funding and Partnerships Drug Discovery and Development, Innovative Treatment Solutions, Clinical Trials and Research, Therapeutic Product Commercialization
Target Customers
Healthcare Professionals, Patients, Medical Researchers, Pharmaceutical Organizations, Investors Patients with Unmet Medical Needs, Healthcare Professionals, Caregivers, Medical Research Community
Taxonomy
Life SciencesPharmaceuticalsOncologyOphthalmologyUrologyImmunology +9 BiopharmaceuticalUrologic Patient CareTherapeutic BreakthroughsVibegronOveractive BladderBenign Prostatic Hyperplasia +9
Website
astellas.com urovant.com
Astellas Pharma logo

About Astellas Pharma

Astellas Pharma, founded in 2005, stands as a prominent player in the global life sciences arena, dedicated to translating innovative science into value for patients. Their slogan, "Astellas is committed to turning innovative science into VALUE for patients," encapsulates their mission of leveraging...

Urovant Sciences logo

About Urovant Sciences

Urovant Sciences, a company founded in 2017 and headquartered in the United States, is now part of Sumitomo Pharma America as of July 2023. This transition marks Urovant's integration into a larger, science-based, technology-driven biopharmaceutical ecosystem focused on delivering therapeutic breakt...

Also comparing in this category

Comparing more than these two?

Get Astellas Pharma, Urovant Sciences and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Astellas Pharma compare?

A PDF of Astellas Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Astellas Pharma was founded in 2005, with 12,296 employees. Astellas Pharma, founded in 2005, stands as a prominent player in the global life sciences arena, dedicated to translating innovative science into value for patients. Their slogan, "Astellas is commit. Urovant Sciences was founded in 2017, based in Irvine, United States, with 97 employees. Urovant Sciences, a company founded in 2017 and headquartered in the United States, is now part of Sumitomo Pharma America as of July 2023. This transition marks Urovant's integration into a larger, s.
Astellas Pharma has raised no disclosed funding and Urovant Sciences $240.00M. Latest stage: Astellas Pharma IPO, Urovant Sciences IPO.
Both list gene therapy among their focus areas.

Compare Astellas Pharma with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Astellas Pharma on 11 Mar 2026, and Urovant Sciences on 23 Apr 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout